In multiple myeloma (MM), angiogenesis is strongly correlated to disease progression and unfavorable outcome, and may be promoted by bone marrow hypoxia. Employing gene-expression profiling, we here identified the pro-angiogenic factor adrenomedullin (AM) as the most highly upregulated gene in MM cells exposed to hypoxia. Malignant plasma cells from the majority of MM patients, belonging to distinct genetic subgroups, aberrantly express AM. Already under normoxic conditions, a subset of MM highly expressed and secreted AM, which could not be further enhanced by hypoxia or cobalt chloride-induced stabilization of hypoxia-inducible factor (HIF)1a. In line with this, expression of AM did not correlate with expression of a panel of established hypoxia-/HIF1a-target genes in MM patients. We demonstrate that MM-driven promotion of endothelial cell proliferation and tube formation is augmented by inducible expression of AM and strongly repressed by inhibition of endogenous and hypoxia-induced AM activity. Together, our results demonstrate that MM cells, both in a hypoxia-dependent and -independent fashion, aberrantly express and secrete AM, which can mediate MM-induced angiogenesis. Thus, AM secretion can be a major driving force for the angiogenic switch observed during MM evolution, which renders AM a putative target for MM therapy.
INTRODUCTION
Multiple myeloma (MM) is a neoplasm characterized by expansion of malignant plasma cells in the bone marrow. The transition of a normal plasma cell to a fully transformed, aggressive myeloma cell is a multistep process, which requires the acquisition of chromosomal translocations and mutations in multiple genes. Most of this evolution takes place in the bone marrow (BM), indicating that the interaction with the BM microenvironment has a critical role in the pathogenesis of MM. 1, 2 In the MMinfiltrated BM, aberrant neovascularization (angiogenesis) is almost invariably present, and is associated with endothelial activation, increased capillary permeability and hyperperfusion. 3, 4 Importantly, BM angiogenesis in MM parallels disease progression and is correlated with poor event-free and overall survival, 5, 6 while after successful treatment, microvessel density returns to normal. 7, 8 The pathogenesis of MM-induced angiogenesis has not yet been fully elucidated. It is driven by genetic alterations in the MM cells resulting in an imbalance between the production of pro-and anti-angiogenic factors by myeloma cells and the microenvironment. This is reflected by elevated levels of proangiogenic factors, including VEGFA, bFGF, and HGF, in the BM plasma and peripheral blood of MM patients. 9 This imbalance results in an 'angiogenic switch', which takes place on the verge of progression of monoclonal gammopathy of undetermined significance (MGUS) to active MM. As some of the important angiogenic factors secreted by myeloma cells, including VEGFA and bFGF, are equally expressed by tumor cells isolated from MGUS, smoldering MM and active MM, 10 it has been suggested that the angiogenic switch could also be the consequence of increasing tumor burden, rather than that of aberrant expression of pro-angiogenic factors alone. In line with this notion, a study by Hose et al. 11 revealed that even normal bone marrow plasma cells (BMPC) have significant pro-angiogenic properties. On the other hand, chronic hypoxia may also have an important role in BM angiogenesis in MM. [12] [13] [14] This is suggested by studies demonstrating stabilization and nuclear localization of the HIF1a protein in malignant plasma cells. 12, 13, 15, 16 Indeed, by employing gene-expression profiling, Colla et al. 13 demonstrated that hypoxia affects the transcriptional and angiogenic profiles of myeloma cells, leading to increased expression of VEGFA and IL-8 among other pro-angiogenic factors. Interestingly, HIF1a protein stabilization and activity in MM cells may also occur under normoxic conditions and can, in collaboration with c-MYC, induce VEGFA-mediated angiogenesis. 15 Together, these findings suggest a central role for the hypoxia-HIF1a axis in MM-related BM angiogenesis.
In the present study, we further explored this possibility by studying the transcriptional response of MM cells to hypoxia, using gene-expression microarrays. Interestingly, we identified the pro-angiogenic factor adrenomedullin (AM) as the most highly hypoxia-induced gene in MM cells. In primary myelomas, AM expression was found to be increased during disease progression from MGUS to MM. In addition, endogenous, ectopically expressed and hypoxia-triggered AM secretion by primary MMs and MM cell lines enhanced angiogenesis. Of note, several MM cell lines and primary MMs expressed high levels of AM under normoxic conditions, suggesting regulation independent of the hypoxiaHIF1a axis. Taken together, our results identify AM as a potential driver of the angiogenic switch and promising therapeutic target in MM.
MATERIALS AND METHODS
Preparation of complementary RNA, microarray hybridization and gene-expression profiling analysis RNA was extracted with the RNeasy Kit (Qiagen, Hilden, Germany) or the SV-total RNA extraction kit (Promega, Fitchburg, WI, USA) and Trizol (Invitrogen Life Technologies, Carslbad, CA, USA), in accordance with the manufacturer's instructions. Biotinylated complementary RNA was amplified with a double in vitro transcription, according to the Affymetrix small sample labeling protocol vII (Affymetrix, Santa Clara, CA, USA). The biotinylated complementary RNA was fragmented and hybridized to the HG-U133 Plus 2.0 GeneChip oligonucleotide arrays according to the manufacturer's instructions (Affymetrix). Fluorescence intensities were quantified and analyzed using the GCOS software (Affymetrix). Arrays were scaled to an average intensity of 100. Differentially expressed genes were identified by a Student's t-test, and P-values were adjusted for multiple comparisons using the Benjamini and Hochberg correction. The threshold for significance was set to a P-value of p0.05. Among those genes, those with a fold change of X2 were retained. Among the genes with a fold change X2 in a given population, those with 100% absent call in this population were considered not to be biologically relevant and were removed. The call ('present' or 'absent') is determined by Affymetrix GCOS software and indicates whether a gene is reliably expressed or not. For a global analysis of AM expression, geneexpression data publically available and deposited in the NIH Gene Expression Omnibus (GEO) National Center for Biotechnology Information (NCBI), http:// www.ncbi.nlm.nih.gov/geo/ under accession number GSE2658, were used. These concerned the U133 Plus 2.0 Affymetrix oligonucleotide microarray data from 559 newly diagnosed MM patients included in total therapy 2/3 (TT2, TT3), provided by the Donna D and Donald M Lambert Laboratory of Myeloma Genetics, University of Arkansas for Medical Sciences, Little Rock, AR, USA. 17 Primary MM samples used for additional studies were obtained during routine diagnostic procedures at the Academic Medical Center, Amsterdam, the Netherlands. Mononuclear cells were harvested by standard Ficoll/Paque density gradient centrifugation (Amersham Pharmacia Biosciences, Roozendaal, the Netherlands) and CD138 þ cells were sorted by positive selection using anti-CD138 antibody (clone BB4, Instruchemie, Delfzijl, the Netherlands) and Dynabead-conjugated goat anti-mouse IgG (Dynal, Oslo, Norway).
NF-kB profile
The MM NF-kB profile was determined by Annuziata et al. 18 Genes comprising the NF-kB profile in MM were those that were decreased in expression by 440% in at least six of eight time points following treatment of L363 cells with IKKb inhibitor (MLN120b) (Millennium Pharmaceuticals, Cambridge, MA, USA) for 8-24 h in three separate experiments (accession number GSE8487). Genes were chosen if they correlated in expression across the MM cell lines (r40.5). NF-kB profile genes, using Affymetrix U133 Plus 2.0 data, relied on the following probe sets:
Cell culture Human myeloma cell lines (HMCLs) L363, UM-1, OPM-1, NCI-H929 and RPMI8226 were cultured in RPMI medium 1640 (Invitrogen Life Technologies) containing 10% clone I serum (HyClone, Waltham, MA, USA), 100 units per ml of penicillin, and 100 mg per ml of streptomycin. LME-1 cell line was cultured in IMDM medium (Invitrogen Life Technologies) supplemented with transferrin (20 mg/ml) and b-mercaptoethanol (50 mM). An AM cDNA doxycycline-inducible NCI-H929 cell line (NCI-H929/TR/AM) was generated as described previously, using the T-REx System (Invitrogen Life technologies). 19 AM overexpression was obtained by incubating NCI-H929/TR/AM cells for 24 h with 0.2 mg/ml doxycycline. Conditioned medium was harvested from 48 h cultures initiated at a concentration of 10 6 cells/ml in RPMI 10% FCS medium. Control medium (RPMI 10% FCS) was pretreated for 48 h in 37 1C next to conditioned medium. NF-kB stimulation was performed by culturing MM cells (at a concentration of 10 6 cells/ml in RPMI medium containing 10% FCS) for 48h with PMA or TNFa (100 ng/ml). The treatment with cobalt chloride (CoCl 2 ) was performed by culturing MM cells (at a concentration of 10 6 cells/ml in RPMI medium containing 10% FCS) for 24 h with the final concentration of CoCl 2 (100 uM).
HUVECs were prepared from human umbilical cord veins as described previously. 20 The adherent endothelial cells (culture flasks were coated with 1% gelatin) were maintained in RPMI medium (Invitrogen Life Technologies) containing 10% clone I serum (HyClone), 10% normal human serum, 3 mg/ml of basic fibroblast growth factor (bFGF), 100 units/ ml of penicillin/streptomycin and 2 mmol/l l-glutamine (complete medium), and incubated at 37 1C in 5% CO 2 . At confluence, the cells were detached by trypsin and used in experiments before the sixth passage.
RT-PCR
Total RNA was isolated using Trizol according to the manufacturer's protocol (Invitrogen Life Technologies). The RNA was further purified using isopropanol precipitation and was concentrated using the RNeasy MinElute Cleanup kit (Qiagen). The quantity of total RNA was measured using a NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). Five microgram of total RNA was used for cDNA synthesis as described previously. 21 The PCR mixture contained: 
. All primers were manufactured by Sigma-Aldrich (Haverhill, UK).
HUVEC proliferation and tube formation assay
HUVECs were plated at a density of 5000 cells/well on pre-coated 96-well plates in 100 ml of RPMI 1640 medium containing 10% FCS and 10% NHS. The next day, the medium was removed and HUVECs were stimulated with MM conditioned medium (CM), harvested from 48 h cultures initiated at a concentration of 10 6 cells/ml in RPMI with 10% FCS. The AM inhibitors (37133 and 16311) were obtained from the laboratory of Frank Cutitta and used at a final concentration of 1 mM. 22 bFGF was used at a final concentration of 3 mg/ml. After 72 h, the number of living cells was determined based on a FSC/SSC dot plot. The results are presented as mean þ / À s.d. of samples assayed in triplicate. All experiments were performed at least three times. Student's t-test was used for statistical data comparison. For the tube formation assay, HUVECs were seeded on matrigel in 15-well m-slide angiogenesis plates, and were stimulated with MM conditioned medium. Cultures were then incubated for 6 h at 37 1C. At the end of the incubation period, from each well, three fields of view were photographed and the number of meshes per field was quantified. The data were expressed as mean ± s.d. of a representative experiment in triplicate.
ELISA and western blot
The concentration of AM in MM supernatants was determined by ELISA (Phoenix Pharmaceutical, Burlingame, CA, USA). MM cell line conditioned media were obtained after 48 h culture at a concentration of 10 6 cells/ml in RPMI 1% FCS medium. Control medium (RPMI 1% FCS) was pre-treated for 48 h at 37 1C. Protein for immunoblotting was harvested from MM cell lines, separated by 10% SDS-polyacrylamide gel electrophoresis and subsequently blotted. The following antibodies were used for immunoblotting: anti-HIF1a polyclonal antibody (NB100-449, Novus Biologicals, Littleton, CO, USA) and anti-b-actin monoclonal antibody (clone AC-15, Sigma-Aldrich, St. Louis, MO, USA). Primary antibodies were detected by HRP-conjugated secondary antibodies, followed by detection using LumiLight PLUS western blotting substrate (Roche, Penzberg, Germany).
Statistical analysis
Nonparametric statistics were used with Prism 5.0 software (Graphpad Software, San Diego, CA, USA). Spearman rank correlation coefficients were used to determine correlations (in 559 newly diagnosed MM patients included in the Total Therapy 2/3 (TT2, TT3) trials between (i) expression of the AM gene and the MM hypoxia target genes, (ii) expression of the AM gene and the NF-kB profile genes, (iii) AM gene and the HOXB7 gene and (iv) expression of the AM gene and the ING4 gene. The Kruskal-Wallis test was used to compare AM gene expression in plasma cells derived from 559 newly diagnosed MM patients treated in the TT2 and TT3 trials, 4 MGUS patients and 22 healthy donors BMPC. Two-tailed t-tests were employed to analyze the in vitro data using Prism 5.0 software (Graphpad Software, San Diego, CA, USA). A P-value of o0.05 was considered to be statistically significant. The gene ontology (GO) biological pathways regulated by hypoxia were identified using DAVID software (Database for Annotations, Visualization and Integrated Discovery). 23 
RESULTS

Transcriptional response of MM cells to hypoxia
To gain a global view of the transcriptional response of multiple myeloma cells to hypoxia, we compared the gene-expression profile of the HMCLs UM-1 and OPM-1 cultured under normoxic and hypoxic conditions for 16 h, using Affymetrix human genome U133 plus 2.0 arrays. HIF1a stabilization, a characteristic response to hypoxic stimulation, was confirmed by immunoblotting ( Figure 1a) . Hypoxia resulted in a consistent 42-fold increase in gene expression of 311 genes in UM-1 cells and 290 genes in OPM-1 cells (Supplementary Table 1 and 2). Importantly, the hypoxic gene-expression signature (Table 1 ) contained many genes that have previously been associated with hypoxia responses and/or represent established HIF1a target genes (underlined in Table 1 ). To identify if any GO classes were enriched in these two differentially expressed gene sets, GO analysis was performed using DAVID bioinformatics resource. The enriched GO 'biological process' categories were found to be enriched with a P-value cutoff of Po0.05 and a fold enrichment X2, and are shown in Supplementary Figures 1 and 2 . Importantly, the 'hypoxia' pathway, as well as pathways known to be regulated in response to hypoxia were found for both cell lines. Those pathways contained many genes that have previously been associated with hypoxia responses and/or represent established HIF1a target genes (underlined in Table 1 ). It comprised genes involved in the metabolic response to hypoxia, including glucose import (SLC2A6 and SLC2A1), glycolysis (PFKFB4, PFKFB3, ALDOC, ENO1, HK2 and HK1), downregulation of oxidative phosphorylation (PDK1 and MXI1); genes involved in cell proliferation and apoptosis (BNIP3, BNIP3L, PRF1, PLEKHF1 and APLP1), genes encoding transcription factors and signaling molecules (SREBF1, JUN, MAF, WDR54, WDR5B, RAB20, RAP1 and GAP) and several pro-angiogenic genes (VEGFA, AM and ANGPTL4). For AM, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-4 (PFKFB4), BCL2/adenovirus E1B 19kDa interacting protein 3 (BNIP3), vascular endothelial growth factor (VEGF), and adenylate-kinase-3-like-1 (AK3L), hypoxia-mediated induction was confirmed by RT-PCR (Figure 1b) . Among the hypoxia-repressed genes were a large group of genes linked to cell proliferation/DNA replication and protein synthesis, energy-costly processes that are typically repressed in response to hypoxic stress (Table 1) .
Interestingly, in both OPM-1 and UM-1 cells, AM was identified as the top-regulated hypoxia target gene, displaying a 48-and 57-fold induction, respectively. The fact that AM has been reported to be a transcriptional target gene of HIF1a 24 and acts as a potent angiogenic factor in a number of solid tumors, prompted us to further investigate its expression, regulation and role in myeloma-induced angiogenesis.
Expression and regulation of AM in HMCLs and primary MM cells To explore the expression and regulation of AM in MM, we initially assessed the AM mRNA and protein expression in a panel of HMCLs cultured under normoxic conditions (Figures 2a-c) . While high or moderate AM mRNA levels were found in L363, LME-1 and RPMI8226, AM expression in the other HMCLs was either low or undetectable (OPM-1, NCI-H929 and UM-1) (Figure 2a) . Immunocytochemical AM protein detection matched these mRNA expression data (Figure 2b) , showing strong cytoplasmic staining of L363, LME-1 and RPMI 8226, but no or very weak AM expression in the other cell lines. In addition, significant quantities of secreted AM protein could also be detected in the culture supernatants of L363 and LME-1 and, at lower levels, of RPMI8226 (Figure 2c ). Hence, under normoxic culture conditions, HMCLs show highly variable levels of AM mRNA and protein expression. As AM is a transcriptional target of HIF1a, 24 high expression of AM in HMCL under normoxic conditions could be a consequence of aberrant HIF1a pathway activation. If so, the AM-positive HMCLs L363, LME-1 and RPMI8226 would be predicted to be positive for an expression-signature comprising multiple HIF1a targets genes. 30 However, AM expression in the tested HMCLs did not correlate with that of other HIF1a/hypoxia target genes (Figure 2d ). This suggests that the normoxic AM expression in L363, LME-1 and RPMI8226 cells is regulated by a HIF1a-independent mechanism.
Next, we subjected all HMCLs to hypoxia, which resulted in effective HIF1a stabilization (Figure 2e) . Interestingly, AM expression was not only strongly induced in OPM-1 and UM-1 cells, but also in NCI-H929 and in RPMI8226 cells, with low and moderate normoxic AM gene expression, respectively. The already high normoxic AM expression in LME-1 and L363 cells was not further increased by hypoxia (Figure 2f upper panel) . A similar induction of AM expression in HMCLs was obtained with CoCl 2 (Figure 2f lower panel). CoCl 2 stabilizes HIF1a by inhibiting prolyl hydroxylase domain-containing proteins (PHDs), which, in normoxic conditions, hydroxylate HIF1a. This hydroxylation is required for interaction of HIF1a with the VHL protein, which targets HIF1a for degradation by the 26S proteasome. 31 Thus, induction of AM expression by treatment with CoCl 2 confirms the role of HIF1a in hypoxia-driven upregulation of AM in MM cells (Figure 2f ).
Expression of AM is related to MM disease progression and molecular subgroup Consistent with the results obtained in HMCLs, primary MMs isolated and processed under standard, that is, non-hypoxic, conditions, also showed highly variable levels of AM mRNA expression ( Figure 3a) . As shown in Figure 3b , hypoxic stimulation of these primary MM cells resulted in an increased AM mRNA levels in cells with low baseline AM expression.
To obtain a global view of AM expression in relation to disease progression and MM molecular subgroup, we analyzed Affymetrix oligonucleotide microarray data from a panel of 559 newly diagnosed MM patients included in total therapy 2/3 (TT2, TT3). 17 Interestingly, this analysis revealed that, compared with expression in normal BMPC, AM expression is already elevated in a small subset of MGUS patients and is markedly increased in the majority of primary MMs (Po0.001) (Figure 3c, left panel) . Further analysis of AM expression in specific MM molecular subgroups, as previously identified by gene-expression profiling (PR, LB, MF, HY, CD1, CD2, MS amd MY), 17 revealed significantly increased AM expression (Po0.05) in the PR, LB, HY, CD2 and MY subgroups compared with BMPC and MGUS patients (Figure 3c,  right panel) . Hence, expression of AM by MM cells is related to disease progression and molecular subgroup.
Adrenomedullin expression in primary MMs is not related to expression of other hypoxia target genes or NF-kB profile genes The data presented above suggest that aberrant expression of AM by MM cells can be driven by hypoxia-dependent as well as hypoxia-independent mechanisms. To further strengthen this notion, we assessed the relation between expression of AM and a panel of 11 'MM hypoxia signature genes' (Supplementary Table 3 ). These genes were selected because they were (i) highly induced by hypoxia in both OPM-1 and UM-1 cells (Supplementary Table 1 and 2), and significantly expressed in at least 10% of primary MM patients; (ii) confirmed to be hypoxia target genes in multiple independent studies; (iii) contained functional hypoxia response elements (HREs) in their promoter. 30 Consistent with our observations in HMCLs, analysis of the TT2/TT3 data set 17 revealed that AM expression in primary MM is not correlated to most of the MM hypoxia signature genes. The only significant correlations found were between AM and PDK1 and HK2 (Supplementary Table 4) ; however, the correlation coefficients were low (o0.2).
As the NF-kB pathway can drive angiogenesis [32] [33] [34] and expression of pro-inflammatory cytokines, including cytokines that can regulate AM, [35] [36] [37] we also assessed the relation between the NF-kB pathway and AM. As shown in Supplementary Table 4 , analysis of the TT2/TT3 data set did not reveal an association between AM expression and expression of NF-kB profile genes, as defined by previous studies in MM. 18 Consistent with this finding, stimulation of the NF-kB pathway in MM cell lines (UM-1 and OPM-1) with PMA or TNFa, as confirmed by the upregulation of established NF-kB target genes, including CD74 and RELB, did not enhance the (low) AM gene expression in these cells (Supplementary Figure 3) .
Other candidate regulators of AM expression and MMinduced angiogenesis are the homeobox gene HOXB7 and the tumor-suppressor gene inhibitor of growth family member 4 (ING4). HOXB7 can mediate tumor-induced angiogenesis, 38 and its expression in MM cells is correlated with that of several proangiogenic factors. 39 However, analysis of the TT2/3 primary MM patients' data set, did not reveal a correlation between HOXB7 and AM gene expression (Supplementary Table 4 ). Similarly, expression of ING4, which represses angiogenesis in solid tumors 40 and is downregulated in MM cells compared with that in normal plasma cells, 41 was not correlated with AM expression (Supplementary Table 4 ).
Adrenomedullin contributes to MM-induced angiogenesis MM cells generally express multiple angiogenic factors. Consequently, MM conditioned media (CM) show significant proangiogenic activity. 11 To assess whether AM can contribute to this activity, we generated NCI-H929 cells with inducible overexpression of AM, by stably transfecting a doxycyclineinducible AM cDNA (NCI-H929/TR/AM). Doxycycline treatment of these cells resulted in a clear induction of AM mRNA, resulting in a seven-fold increase in AM protein level, while doxycyclin treatment of control (NCI-H929/TR) cells did not affect AM expression levels (Figure 4a) . Importantly, as shown in Figure 4b , CM derived from doxycycline-treated NCI-H929/TR/AM cells enhanced proliferation of human umbilical vein endothelial cells (HUVECs), which express the AM receptors CRLR and RAMP2-modifying protein (Supplementary Figure 4) by almost two-fold. Moreover, AM-enriched CM stimulated endothelial mesh formation by almost five-fold (Figure 4c ). Both HUVEC proliferation and angiogenesis were AM-specific, as both were completely abrogated by 37133 and 16311, two highly specific small-molecule AM inhibitors that antagonize signaling by binding AM directly, thereby preventing receptor binding. 22 Of note, by the use of the CM from doxycycline-treated control NCI-H929/TR cells, non-specific effects of doxycycline were excluded and the AM-specificity of the small molecule inhibitors 37133 and 16311 was confirmed (Figure 4b right panel) .
To address whether endogenously produced AM can also contribute to MM-induced angiogenesis, we next assessed the angiogenic properties of CM from L363 MM cells, which produce high levels of AM under normoxic conditions (Figure 2c ). As shown in Figure 5 , CM from L363 cells displayed potent angiogenic activity, promoting HUVEC proliferation, which was decreased two-fold by treatment with 16311 and 37133, respectively (Figure 5a ) Furthermore, blocking AM by 16311 and 37133 decreased L363 CM induced mesh formation approximately two-fold (Figure 5b ). Taken together, these data demonstrate that overexpression of AM by malignant plasma cells can significantly contribute to their pro-angiogenic properties.
To determine whether hypoxia-driven AM secretion by primary MM cells can contribute directly to MM-induced angiogenesis, two independent primary MM cell samples were subjected to hypoxia and AM expression and angiogenic potential were investigated. Exposure to hypoxia resulted in a clear increase in AM mRNA levels in both primary MM cell samples (Figure 5c ), as well as in an increased AM protein secretion (1.6-and 3.2-fold in MM1 and 2, respectively) (Figure 5d ). Functionally, this hypoxiadriven AM secretion resulted in an approximately two-fold increase in HUVEC numbers, that was inhibited to normoxic or subnormoxic levels by blocking AM signaling with 16311. Importantly, 16311 did not influence bFGF-induced HUVEC proliferation, confirming specificity of the inhibition (Figure 5e ). Taken together, these results demonstrate that AM is a key mediator of angiogenesis in MM, strongly upregulated under hypoxic conditions.
DISCUSSION
In this study, we explored the transcriptional response of MM cells to hypoxia, by comparing the gene expression profile of the HMCLs UM-1 and OPM-1 under normoxic and hypoxic conditions. The hypoxia-induced gene expression signature of these MM cells (Table 1, Supplementary Table 1 and 2, Figure 1 ) contained multiple genes that have previously been associated with hypoxia responses and/or represent established HIF1a target genes, including genes involved in the metabolic response to hypoxia, in cell proliferation and apoptosis. Furthermore, it comprised several pro-angiogenic genes, including VEGFA, ANGPTL4 and AM, of which AM was identified as the top-regulated gene (40-50-fold induction). Interestingly, however, although AM is a well-established HIF1a target gene containing HRE sites in its promoter, as major regulatory sequences, 42 we observed that several HMCLs and primary MMs also expressed high levels of AM under normoxic conditions (Figures 2a-c) . Importantly, MM cells with normoxic AM expression did not show aberrant normoxic HIF1a stabilization and displayed no overexpression of other HIF1a/hypoxia target genes (Figures 2d-f) , suggesting normoxic regulation of AM expression by HIF1a-independent mechanisms. In line with this notion, our analysis of a large MM gene-expression data set 17 revealed no consistent correlation between AM expression and expression of other hypoxia/HIF1a target genes. These findings imply that mechanisms other than hypoxia can contribute to AM expression in malignant plasma cells, and are consistent with a scenario in which both HIF1a-dependent and independent mechanisms contribute to the 'angiogenic switch' in MM.
We observed that AM expression in malignant plasma cells of MM patients is significantly higher than in normal BMPC or plasma cells patients with MGUS (Figure 3c ). This elevated AM expression was present in most molecular MM subgroups (PR, LB, HY, CD2 and MY) (Figure 3d ). Hence, AM overexpression is related to disease progression, suggesting that AM may have an important functional contribution in angiogenesis, which is associated with progression of MGUS to clinically overt MM. 43 Our functional studies strongly support this scenario as they demonstrate that (i) endogenous, hypoxia-induced and ectopic expression of AM in MM cells strongly promotes angiogenic activity of MM cells, as shown by enhanced endothelial cell proliferation and mesh formation ( Figures 4 and 5) ; (ii) blockage of AM strongly reduces the pro-angiogenic activity of MM cells ( Figure 5 ).
Adrenomedullin is involved in blood vessel morphogenesis, vasculogenesis and tumor angiogenesis. 29, 44 AM-null mice die in utero as a result of defective vasculogenesis, 45 while AM overexpression by tumors mediates tumor angiogenesis. 26, 28, 46 In addition, AM can directly promote tumor growth. 25, 47 AM stimulates angiogenesis by binding the CRLR, which is widely expressed on normal and hypoxic endothelial cells. 48 Interestingly, binding of AM to the CRLR/RAMP2 can transactivate the VEGFR-2, which is responsible for most pro-angiogenic effects of VEGFA 49 , including the stimulation of endothelial cell differentiation, proliferation, migration and morphogenesis. This AM-induced VEGFR-2 transactivation does not require VEGFA, suggesting that AM can functionally mimic VEGFA, and thereby contribute to MM-induced angiogenesis. Although it has recently been suggested that HIF1a is a major regulator of the pro-angiogenic profile of myeloma cells and of MM-induced angiogenesis, deregulation of other transcriptional pathways may potentially also contribute to the angiogenic switch and overexpression of AM in MM. Since pro-inflammatory cytokines have been shown to induce increased AM secretion, [35] [36] [37] we explored the role of NF-kB signaling in the regulation of AM. However, expression of NF-kB profile genes and AM in primary MM patients (Supplementary Table 4) were not correlated. Moreover, stimulation of the NF-kB pathway in MM cells in vitro did not influence expression of AM (Supplementary Figure 3) , suggesting that the NF-kB pathway is not involved in the regulation of AM in malignant plasma cells. Other candidate regulators of AM expression and MM-induced angiogenesis are the homeobox gene HOXB7 and the tumor-suppressor gene inhibitor of growth family member 4 (ING4). HOXB7 has been shown to mediate tumor-induced angiogenesis and tumor progression in solid cancers by regulating VEGF, IL-8, bFGF2 and Ang-2. 38 In MM cells, HOXB7 expression is correlated with and can control overexpression of several pro-angiogenic factors. 39 However, our analysis of the TT2/3 primary MM patients' data set, did not reveal a correlation between HOXB7 and AM gene expression (Supplementary Table 4 ). Similarly, expression of ING4, which acts as a repressor of angiogenesis in solid tumors 40 and shown reduced expression in MM cells compared with normal plasma cells, 41 was not correlated with AM expression (supplementary Table 4 ). Hence, neither NF-kB, HOXB7 nor ING4, appear to have a role in AM deregulation in MM plasma cells, and further studies are needed to unravel the molecular mechanism(s) involved.
In conclusion, our results demonstrate that MM cells, both in a hypoxia-dependent and -independent fashion, aberrantly express and secrete AM, which can mediate MM-induced angiogenesis. This aberrant AM expression could be a major driving force for the angiogenic switch observed during MM progression, which renders AM a putative target for anti-angiogenic therapy in MM. 
